论文部分内容阅读
目的:观察头孢哌酮舒巴坦应用于肾盂肾炎治疗的临床疗效。方法:以我院收治的76例肾盂肾炎患者为研究对象,随机将其分为观察组(38例)与对照组(38例)。给予观察组头孢哌酮舒巴坦,给予对照组左氧氟沙星,比较两组疗效和不良反应发生情况。结果:观察组总有效率为94.74%,对照组为78.95%,组间差异有统计学意义(P<0.05)。观察组不良反应发生率为15.79%,对照组为13.16%,组间差异无统计学意义(P>0.05)。结论:头孢哌酮舒巴坦是治疗肾盂肾炎的理想药物,值得推广。
Objective: To observe the clinical efficacy of cefoperazone sulbactam in the treatment of pyelonephritis. Methods: A total of 76 patients with pyelonephritis treated in our hospital were randomly divided into observation group (38 cases) and control group (38 cases). The observation group was given cefoperazone sulbactam, and the control group was given levofloxacin. The curative effect and adverse reactions of the two groups were compared. Results: The total effective rate was 94.74% in the observation group and 78.95% in the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 15.79% and in the control group was 13.16%. There was no significant difference between the two groups (P> 0.05). Conclusion: Cefoperazone sulbactam is an ideal drug for the treatment of pyelonephritis, which is worth promoting.